These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34560229)

  • 1. Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth.
    Pi R; Yang Y; Hu X; Li H; Shi H; Liu Y; Wang X; Tong A; Lu T; Wei Y; Zhao X; Wei X
    Cancer Lett; 2021 Dec; 523():72-81. PubMed ID: 34560229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
    Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
    Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
    Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
    Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells.
    Li S; Sheng J; Liu Z; Fan Y; Zhang C; Lv T; Hu S; Jin J; Yu W; Song Y
    J Cell Mol Med; 2021 Mar; 25(5):2436-2449. PubMed ID: 33507584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
    Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mTORC1 inhibitor rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory.
    MacCallum PE; Blundell J
    Psychopharmacology (Berl); 2020 Sep; 237(9):2795-2808. PubMed ID: 32601986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
    Eyre TA; Hildyard C; Hamblin A; Ali AS; Houlton A; Hopkins L; Royston D; Linton KM; Pettitt A; Rule S; Cwynarski K; Barrington SF; Warbey V; Wrench D; Barrans S; Hirst CS; Panchal A; Roudier MP; Harrington EA; Davies A; Collins GP
    Hematol Oncol; 2019 Oct; 37(4):352-359. PubMed ID: 31385336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.
    Mizutani Y; Inase A; Maimaitili Y; Miyata Y; Kitao A; Matsumoto H; Kawaguchi K; Higashime A; Goto H; Kurata K; Yakushijin K; Minami H; Matsuoka H
    Int J Hematol; 2019 Oct; 110(4):490-499. PubMed ID: 31286402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection.
    Fantus D; Dai H; Ono Y; Watson A; Yokota S; Mohib K; Yoshida O; Ross MA; Watkins SC; Ramaswami B; Valusjkikh A; Rothstein DM; Thomson AW
    Transplantation; 2017 Dec; 101(12):2830-2840. PubMed ID: 28885497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antitumor effects of AZD2014, a dual mTORC1/2 inhibitor, against human hepatocellular carcinoma xenograft in nude mice].
    Liao H; Wang Y; Xu X; Zhou C; Zhang J; Zhong K; Yang D
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jul; 41(7):1056-1061. PubMed ID: 34308856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma.
    Flannery PC; DeSisto JA; Amani V; Venkataraman S; Lemma RT; Prince EW; Donson A; Moroze EE; Hoffman L; Levy JMM; Foreman N; Vibhakar R; Green AL
    Oncol Rep; 2018 Feb; 39(2):455-464. PubMed ID: 29207163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest.
    Yu CC; Huang HB; Hung SK; Liao HF; Lee CC; Lin HY; Li SC; Ho HC; Hung CL; Su YC
    PLoS One; 2016; 11(3):e0151942. PubMed ID: 27031247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
    Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
    BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTORC1/2 Inhibitor Served as a More Ideal Agent Against the Growth of Mouse Lymphocytic Leukemia Both
    Liao HF; Lin YZ; Yu CC; Tai TS; Hung SK; Yang CC; Su YC
    Anticancer Res; 2019 Sep; 39(9):4829-4835. PubMed ID: 31519585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
    Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
    Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
    Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
    Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
    Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
    Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the novel mTOR inhibitor AZD2014 in neuronal ischemia.
    Hadley G; Beard DJ; Alexopoulou Z; Sutherland BA; Buchan AM
    Neurosci Lett; 2019 Jul; 706():223-230. PubMed ID: 31100427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
    Komura N; Mabuchi S; Shimura K; Yokoi E; Kozasa K; Kuroda H; Takahashi R; Sasano T; Kawano M; Matsumoto Y; Kodama M; Hashimoto K; Sawada K; Kimura T
    Cancer Immunol Immunother; 2020 Dec; 69(12):2477-2499. PubMed ID: 32561967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.